PROVECTUS BIOPHARMACEUTICALS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations
PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT) reported Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations of 412.50 thousand shares for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-26.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations · last filed 2026-03-26
- PROVECTUS BIOPHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, forfeitures and expirations for the quarter ending 2023-12-31 was 25.00K shares, a 100.00% increase year-over-year.
- PROVECTUS BIOPHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, forfeitures and expirations for the quarter ending 2022-12-31 was 12.50K shares.
- PROVECTUS BIOPHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, forfeitures and expirations for the quarter ending 2021-12-31 was 0.00 shares.
- PROVECTUS BIOPHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, forfeitures and expirations for fiscal 2024 was 412.50K shares, a 560.00% increase from fiscal 2023.
- PROVECTUS BIOPHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, forfeitures and expirations for fiscal 2023 was 62.50K shares, a 66.67% increase from fiscal 2022.
- PROVECTUS BIOPHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, forfeitures and expirations for fiscal 2022 was 37.50K shares, a 99.95% decline from fiscal 2021.
- PROVECTUS BIOPHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, forfeitures and expirations for fiscal 2021 was 68.72M shares, a 121.31% increase from fiscal 2020.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations 0 month | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations 12 month |
|---|---|---|---|---|
| 2024-12-31 | 412.50K shares 10-K · filed 2026-03-26 | |||
| 2023-12-31 | 25.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | 62.50K shares 10-K · filed 2025-03-28 | ||
| 2023-09-30 | 37.50K shares 10-Q · filed 2023-11-14 | |||
| 2022-12-31 | 12.50K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | 37.50K shares 10-K · filed 2024-03-28 | ||
| 2022-09-30 | 25.00K shares 10-Q · filed 2022-11-09 | |||
| 2021-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | 68.72M shares 10-K · filed 2023-03-30 | ||
| 2021-09-30 | 68.72M shares 10-Q · filed 2021-11-10 | |||
| 2021-08-30 | 68.72M shares 10-K · filed 2023-03-30 | |||
| 2020-12-31 | 31.05M shares 10-K · filed 2022-03-29 | |||
| 2019-12-31 | 6.09M shares 10-K · filed 2021-03-02 |